

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property
Organization
International Bureau

(43) International Publication Date
17 April 2025 (17.04.2025)



(10) International Publication Number
WO 2025/079020 A1

(51) International Patent Classification:

C07K 16/28 (2006.01) A61P 35/00 (2006.01)
A61K 39/395 (2006.01) A61K 31/00 (2006.01)

(21) International Application Number:

PCT/IB2024/059967

(22) International Filing Date:

11 October 2024 (11.10.2024)

(25) Filing Language:

English

(26) Publication Language:

English

(30) Priority Data:

63/543,778 12 October 2023 (12.10.2023) US
63/564,670 13 March 2024 (13.03.2024) US

(71) Applicant: JANSSEN BIOTECH, INC. [US/US];
800/850 Ridgeview Drive, Horsham, Pennsylvania 19044
(US).

(72) Inventor: KNOBLAUCH, Roland; 1400 McKean Road,
Spring House, Pennsylvania 19477 (US).

(74) Agent: LANE, David A. et al.; One Johnson & Johnson
Plaza, Johnson & Johnson, New Brunswick, New Jersey
08933 (US).

(81) Designated States (unless otherwise indicated, for every
kind of national protection available): AE, AG, AL, AM,
AO, AT, AU, AZ, BA, BB, BG, BH, BN, BR, BW, BY, BZ,
CA, CH, CL, CN, CO, CR, CU, CV, CZ, DE, DJ, DK, DM,
DO, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, GT,
HN, HR, HU, ID, IL, IN, IQ, IR, IS, IT, JM, JO, JP, KE, KG,
KH, KN, KP, KR, KW, KZ, LA, LC, LK, LR, LS, LU, LY,
MA, MD, MG, MK, MN, MU, MW, MX, MY, MZ, NA,
NG, NI, NO, NZ, OM, PA, PE, PG, PH, PL, PT, QA, RO,
RS, RU, RW, SA, SC, SD, SE, SG, SK, SL, ST, SV, SY, TH,
TJ, TM, TN, TR, TT, TZ, UA, UG, US, UZ, VC, VN, WS,
ZA, ZM, ZW.

(84) Designated States (unless otherwise indicated, for every
kind of regional protection available): ARIPO (BW, CV,
GH, GM, KE, LR, LS, MW, MZ, NA, RW, SC, SD, SL, ST,
SZ, TZ, UG, ZM, ZW), Eurasian (AM, AZ, BY, KG, KZ,
RU, TJ, TM), European (AL, AT, BE, BG, CH, CY, CZ,
DE, DK, EE, ES, FI, FR, GB, GR, HR, HU, IE, IS, IT, LT,
LU, LV, MC, ME, MK, MT, NL, NO, PL, PT, RO, RS, SE,
SI, SK, SM, TR), OAPI (BF, BJ, CF, CG, CI, CM, GA, GN,
GQ, GW, KM, ML, MR, NE, SN, TD, TG).

Declarations under Rule 4.17:

- as to applicant's entitlement to apply for and be granted a patent (Rule 4.17(ii))
- as to the applicant's entitlement to claim the priority of the earlier application (Rule 4.17(iii))

Published:

- with international search report (Art. 21(3))
- before the expiration of the time limit for amending the claims and to be republished in the event of receipt of amendments (Rule 48.2(h))
- with sequence listing part of description (Rule 5.2(a))
- in black and white; the international application as filed contained color or greyscale and is available for download from PATENTSCOPE

(54) Title: FIRST LINE TREATMENT IN EGFR EXON 20 INSERTION-MUTATED ADVANCED NON-SMALL CELL LUNG CANCER

(57) Abstract: The present disclosure provides methods for treating EGFR-positive non-small cell lung cancer (NSCLC) in a subject that is treatment naïve.



WO 2025/079020 A1